 Selective mitoKATP blockade with 5-hydroxydecanoic acid (“5-HD”) or MCC-134 completely inhibits the cardioprotection afforded by IPC, and genetic knockout of sarcKATP genes.in mice has been shown to increase the basal level of injury compared to wild type mice.This baseline protection is believed to be a result of sarcKATP’s ability to prevent cellular Ca2+ overloading and depression of force development during muscle contraction, thereby conserving scarce energy resources.